This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Xianyin Lai: Innovator in Diabetes and Obesity Treatment
Introduction
Xianyin Lai is a notable inventor based in Carmel, IN, who has made significant contributions to the field of pharmaceuticals. His work primarily focuses on developing innovative compounds that target specific receptors related to diabetes and obesity.
Latest Patents
Xianyin Lai holds a patent for GIP/GLP1 co-agonist compounds. This invention relates to compounds that exhibit activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The compounds are designed to have an extended duration of action at these receptors and can be administered orally. They may prove beneficial in treating type 2 diabetes mellitus (T2DM) and obesity.
Career Highlights
Xianyin Lai is associated with Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has positioned him as a key player in the development of treatments for chronic conditions such as diabetes and obesity.
Collaborations
Xianyin has collaborated with notable colleagues, including Milata Mary Abraham and Jorge Alsina-Fernandez, to advance research and development in his field.
Conclusion
Xianyin Lai's innovative work in developing GIP/GLP1 co-agonist compounds highlights his commitment to improving treatment options for diabetes and obesity. His contributions are paving the way for future advancements in pharmaceutical therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile